Analysts raised targets broadly on Friday, with upgrades spanning pharma, real estate, and financial services.
ABBV led the healthcare moves. The average analyst target climbed to $273.86. AbbVie carries a market cap above $434 billion. Short interest sits at just 1.3% of free float — bears are not pressing the stock.
Alexandria Real Estate Equities attracted a target hike to $52.36. The life-science REIT has been under pressure, with short interest at 5.2% of free float. The upgrade signal is notable given the stock's bearish positioning.
Diamondback Energy was the main downward revision. Analysts trimmed the average target slightly to $232.75. The oil producer faces headwinds from softer crude prices. Short interest is modest at 4.4% of free float.
Paramount Skydance saw the consensus target drop to $9.81. The media company carries the highest short interest in today's batch at 9.7% of free float. Analysts remain divided — seven buys versus three sells.
Amgen received a target lift to $378.31. The biotech stock has a mixed analyst split. Four buys face 13 sells, keeping sentiment cautious despite the price target bump.
This is not financial advice.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
